Cerus Corporation (CERS) Stock Price & How to Invest
Last updated November 2026
Short answer
Cerus Corporation (NASDAQ: CERS) sells the INTERCEPT Blood System, which inactivates pathogens in donated platelets and plasma, plus a fibrinogen product made from treated plasma. It is a real, growing medical-device business near breakeven, with ~$227M in trailing revenue against a ~$385M market cap as of November 20, 2026. Its Phase III red blood cell trial (RedeS) met its main goal in November 2026, and the open questions now are FDA and European approval timing, margins and a thin cash cushion.
CERS stock price
As of 2026-11-20, Cerus Corporation (CERS) last closed at $1.85, up 14.2% over the past year. Over the past 52 weeks it has traded between $1.62 and $3.28.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Cerus Corporation's investor relations page. Walnut is informational, not investment advice.
CERS key stats
At $1.85 on November 20, 2026, Cerus Corporation (CERS) has a market cap of $374M.
- Market cap
- $374M
- P/E (forward)
- 123.3
- Price to book
- 4.9
- Beta
- 1.85
Market cap, P/E and yield are measured at the $1.85 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Cerus Corporation (CERS)?
The last two weeks for Cerus Corporation, as of November 22, 2026: the price move, the next earnings date, and what analysts changed.
- CERS closed at $1.85 on November 20, 2026, down 7.0% over the past five trading days (from $1.99).
Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Cerus Corporation (CERS) do?
Cerus Corporation, based in Concord, California, makes the INTERCEPT Blood System, a technology that treats donated blood components so that viruses, bacteria, parasites and white blood cells cannot replicate. The process uses amotosalen, a compound that binds to DNA and RNA, activated by ultraviolet A light in a device called an illuminator. INTERCEPT is approved for platelets and plasma in the US and Europe and is used by blood centers in dozens of countries. Cerus sells the disposable treatment kits, which is where most revenue comes from, plus the illuminators. A second product, INTERCEPT Fibrinogen Complex (IFC), is made from pathogen-reduced plasma and used to control bleeding, mostly in US hospitals. The company also earns government contract revenue from BARDA, the US agency funding its red blood cell program.
Recent results show steady, unspectacular growth. In the third quarter of 2026, reported November 2, product revenue rose about 10% to ~$57.7M, and total revenue including ~$6.3M of government contract revenue was ~$64.0M, up about 6%. The net loss shrank to ~$0.6M (about $0.00 per share, a cent better than the consensus estimate of a $0.01 loss) and non-GAAP adjusted EBITDA was positive at ~$5.7M. Management reiterated 2026 product revenue guidance of ~$229M to $231M, including ~$23M to $25M from IFC. Product gross margin was ~52.4%, still below the ~53.4% of a year earlier because of a weaker dollar and higher costs, though better than the ~51% of the second quarter.
The same day, Cerus said the Phase III RedeS trial of INTERCEPT red blood cells met its primary endpoint: treated red cells were non-inferior to conventional units on hemoglobin increment. The stock did not rally on the news. As of November 20, 2026, shares closed at ~$1.90, down about 18% over one month, about 30% over three months and about 3% year to date, though still up about 28% over one year. At roughly 1.7 times trailing revenue, the market is still discounting years of losses, margins in the low 50s, a balance sheet with ~$57M of cash against ~$75M of debt, and the long wait before any red cell approval turns into revenue. The FDA has not yet reviewed the final RedeS study report, and the European CE Mark review continues.
What's driving Cerus Corporation (CERS)?
1. Platelet and plasma kit volume
The core of Cerus is recurring disposable kit sales to blood centers, and that engine is still growing. Product revenue was ~$57.7M in Q3 2026, up about 10% year over year, and reiterated full-year guidance of ~$229M to $231M implies 11% to 12% growth on 2025. In the US, adoption accelerated after the FDA's guidance on bacterial risk control in platelets pushed blood centers toward pathogen reduction or extra testing. Each blood center that converts tends to stay converted, because the process gets built into its workflow and regulatory filings. That makes the revenue base sticky, but it also means growth comes from slowly winning centers and countries, not from sudden demand spikes.
2. INTERCEPT Fibrinogen Complex
IFC is the fastest-growing part of the business. It is a fibrinogen-rich product made from pathogen-reduced plasma, used by hospitals to treat massive bleeding in trauma, obstetrics and cardiac surgery. Management kept the 2026 IFC outlook at ~$23M to $25M in November, after demand grew about 43% in Q2. At roughly a tenth of product revenue it is still small, but it lets Cerus sell into hospitals as well as blood centers, and it uses plasma Cerus already treats. The constraint is manufacturing capacity and hospital adoption, which moves one formulary committee at a time. Continued 30% to 40% growth would add several percentage points to overall company growth.
3. Red blood cell approvals
Red blood cells are the most transfused blood component, with far more units used each year than platelets, so an approved INTERCEPT red cell system would multiply Cerus's addressable market. In November 2026 the US Phase III RedeS trial, supported by BARDA, met its primary endpoint: hemoglobin increment was ~1.996 g/dL with INTERCEPT red cells against ~2.050 g/dL for conventional units, inside the pre-set non-inferiority margin. Related adverse events were similar (3.4% vs 2.5%), but 2.2% of treated patients developed INTERCEPT-specific antibodies, which Cerus describes as low-titer and transient with no clinical impact; regulators will look closely at that. The FDA has not yet reviewed the final study report, and the company gave no filing date. In Europe, the CE Mark review is still under way after an earlier submission ended without approval in 2024. Commercial revenue from red cells would likely take years to ramp after any approval.
4. The INT200 illuminator and profitability
Cerus submitted a premarket approval application to the FDA for its next-generation INT200 illuminator for platelets, and that review is still pending, with a decision previously guided to early 2027. A newer, higher-throughput device matters because blood centers weigh labor and space when deciding whether to adopt pathogen reduction. On the financial side, the company is very close to breakeven: Q3 2026 adjusted EBITDA was positive at ~$5.7M and the GAAP net loss was only ~$0.6M. Getting to sustained GAAP profit depends on lifting product gross margin, which was ~52.4% in Q3 2026 against ~53.4% a year earlier. Analysts on average expect roughly breakeven EPS in 2026 and a small profit of about $0.01 per share in 2027, so leverage depends heavily on cost control.
What are the risks to Cerus Corporation (CERS)?
The biggest specific risk is still regulatory. RedeS met its primary endpoint, but the FDA has not reviewed the final study report, the trial found treatment-specific antibodies in 2.2% of INTERCEPT patients, and Cerus has not said when it will file. The red cell program has a history of delays, including a European CE Mark review that ended without approval in 2024, so a slow or demanding review would push the main growth catalyst further out. Second, margins remain under pressure: product gross margin was ~52.4% in Q3 2026 against ~53.4% a year earlier, partly because most sales are in euros and partly because of input cost inflation, and currency swings can cut either direction. Third, the balance sheet is thin for a company still funding late-stage development: cash and short-term investments were ~$57M at September 30, 2026, against ~$75M of debt. If losses widen or approval work gets expensive, Cerus could raise equity at a share price below $2, diluting holders. Fourth, customer concentration is real, since a handful of large blood center networks and national blood services account for a large share of sales. Finally, competing approaches such as cold-stored platelets, rapid bacterial testing and rival pathogen reduction systems could slow adoption, and BARDA funding depends on US government budgets. The share price itself has been volatile, falling about 30% in the three months to November 20, 2026.
What is the Cerus Corporation (CERS) forecast?
4 analysts publish price targets on CERS, averaging $5.12 as of November 2026, or +176.8% against the $1.85 share price on November 20, 2026. The published targets run from $4.00 to $6.50, a moderate spread, and the ratings split 4 buy, 0 hold, 0 sell. Over the last six months there have been 0 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full CERS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is CERS a buy or a sell?
We give no verdict on Cerus Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Platelet and plasma kit volume. The core of Cerus is recurring disposable kit sales to blood centers, and that engine is still growing. The most optimistic published target, $6.50, assumes this works close to its best case.
The case against. The biggest specific risk is still regulatory. The most pessimistic target, $4.00, is roughly what CERS is worth if this bites instead.
Read the full bull and bear case on CERS, including what would have to change to break either one. Walnut is not an investment adviser.
How is Cerus Corporation (CERS) valued?
Market cap, P/E and dividend yield at today's price are in the CERS key stats above. The business figures below come from Cerus Corporation's reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$227M (latest quarter up ~10% yoy)
- 2026 product revenue guidance: ~$229M to $231M (reiterated)
- Net income (TTM): ~-$7M (EPS ~-$0.04)
- Product gross margin (Q3 2026): ~52%
- Cash / debt (Sep 30, 2026): ~$57M / ~$75M
As of November 2026: At ~$1.90 a share on November 20, 2026, Cerus is valued at roughly 1.7 times trailing revenue, a low multiple next to many medical device peers, which reflects its history of losses, growth near 10% and margins in the low 50s. The company is close to breakeven, with positive adjusted EBITDA of ~$5.7M in Q3 2026 and a GAAP loss of only ~$0.6M, but trailing earnings are still negative, so a trailing P/E is not meaningful and the forward P/E of ~127x rests on a tiny expected profit. The four analysts tracked by Yahoo Finance have a mean price target of ~$5.12, far above the current price, which shows how much of the red blood cell outcome the market is still discounting.
Who competes with Cerus Corporation (CERS)?
Other pathogen reduction systems
Terumo Blood and Cell Technologies sells the Mirasol system, which uses riboflavin and UV light to treat platelets and plasma in several markets outside the US, and Macopharma has developed THERAFLEX UV technology. These are the most direct rivals, although INTERCEPT holds the broadest set of approvals, including US FDA approval for platelets and plasma.
Bacterial testing and cold storage
Instead of inactivating pathogens, many blood centers manage platelet risk with large-volume delayed bacterial culture, rapid tests such as Verax's Platelet PGD test, or by storing platelets cold. These alternatives are the main reason US adoption of pathogen reduction is not universal, and they compete for the same blood center budgets.
Fibrinogen products
IFC competes with traditional cryoprecipitate made by blood centers and with plasma-derived fibrinogen concentrates such as CSL Behring's RiaSTAP and Octapharma's Fibryga. Hospitals choose based on cost, speed of thawing and availability, and the large plasma fractionators have far greater scale and sales reach than Cerus.
What stocks are similar to Cerus Corporation (CERS)?
Other names that sit close to CERS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Cerus Corporation (CERS)
There are three common ways to get CERS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CERS sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where CERS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Cerus Corporation (CERS)
Cerus is a niche blood-safety franchise growing about 10% a year and close to breakeven. At ~$1.90 (November 20, 2026) the stock prices modest growth even after a positive red blood cell trial; regulatory timing for red cells is still the swing factor.
More on Cerus Corporation (CERS)
Whether CERS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CERS a buy or a sell?, and where the stock could go from here in the CERS stock forecast.
For income investors, whether CERS pays a dividend and how the payout looks is covered in does CERS pay a dividend? And to weigh CERS against a peer, read the full side-by-side comparisons: CERS vs CSL and CERS vs HNGE.
Wondering how CERS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Cerus Corporation
Ask Walnut's AI anything about CERS and see how it fits what you own.
FAQ
What does Cerus Corporation do?
+
Cerus makes the INTERCEPT Blood System, which treats donated platelets and plasma so that viruses, bacteria, parasites and white blood cells in them cannot replicate. The process uses a compound called amotosalen that binds to genetic material, activated by ultraviolet light in an illuminator device. Blood centers buy single-use treatment kits for each unit they process, so most revenue is recurring. Cerus also sells INTERCEPT Fibrinogen Complex, a bleeding-control product made from treated plasma, to US hospitals, and it receives contract funding from the US government agency BARDA to develop a red blood cell version, which met its main goal in a Phase III trial in November 2026. The company is headquartered in Concord, California, and generates the majority of its product revenue in Europe, the Middle East and Africa, with the US as its second large market.
How do you invest in CERS stock?
+
Cerus trades on the Nasdaq under the ticker CERS, so shares can be bought through essentially any US brokerage account, and many brokers allow fractional shares at its ~$1.90 price (November 20, 2026). Because it is a small-cap company with a ~$385M market value, it can be volatile and may move sharply on regulatory news such as red blood cell filings or approvals. Some investors get exposure indirectly through small-cap healthcare or medical device funds, where Cerus would be a small weight. Before deciding anything, it is worth reading the company's latest 10-Q and earnings release, and considering how a single small-cap device stock fits within a diversified portfolio. Walnut is not an investment adviser, and this page describes the company without recommending any trade.
Is Cerus profitable?
+
Not on a GAAP basis yet, but it is very close. In the third quarter of 2026 Cerus reported a net loss attributable to the company of ~$0.6M, or about $0.00 per share, and over the trailing twelve months the net loss was ~$7M. On a non-GAAP basis, adjusted EBITDA was positive at ~$5.7M in the quarter, up from ~$5.0M a year earlier. That progress comes from steady revenue growth and expense discipline. The main obstacle to further improvement is product gross margin, which was ~52.4% against ~53.4% a year earlier because of a weaker dollar against the euro and higher product costs. Analysts on average expect roughly breakeven results for 2026 and about $0.01 of EPS in 2027. Sustained GAAP profitability likely depends on margin recovery, continued kit volume growth and how much the company spends on red blood cell approval work.
Why is Cerus stock so cheap?
+
At ~$1.90 a share and ~1.7 times trailing revenue (November 20, 2026), Cerus trades at a low multiple for a medical device company with recurring sales. Several things explain the discount. The company has posted losses for most of its history, so investors have been reluctant to pay for future profits. Growth of around 10% a year is solid but not fast. Gross margins near 52% are below many device peers. The cash balance of ~$57M sits below ~$75M of debt, which raises the possibility of future share issuance. And the red blood cell program, the biggest potential upside, still needs FDA and European approval after repeated delays, even though the RedeS trial met its primary endpoint. A low share price does not by itself mean the stock is undervalued; it reflects the market's current weighting of these factors.
What is the INTERCEPT red blood cell program and why does it matter?
+
Red blood cells are the most commonly transfused blood component, so a pathogen reduction system for them would expand Cerus's addressable market far beyond platelets and plasma. In the US, the Phase III RedeS trial, funded in part by BARDA, reported top-line results on November 2, 2026: INTERCEPT red cells were non-inferior to conventional units on hemoglobin increment, with similar rates of related adverse events, though 2.2% of treated patients developed low-titer INTERCEPT-specific antibodies. The FDA has not yet reviewed the final study report and Cerus has not given a filing date. A separate US trial called ReCePI produced positive results, which were added to the company's European CE Mark application, and that review is still ongoing after an earlier submission concluded without approval in October 2024. Even with approval, revenue would take years to build as blood centers validate and adopt a new process.
When does Cerus report earnings next?
+
Cerus reported its third quarter 2026 results on November 2, 2026, so the next report, covering the fourth quarter and full year 2026, would typically come in late February or early March 2027; the company had not announced a date as of November 20, 2026. Analysts on average expect fourth-quarter revenue of ~$64.7M and roughly breakeven EPS. Key things the market typically watches are product revenue against the ~$229M to $231M full-year guidance, IFC sales against the ~$23M to $25M outlook, product gross margin, which was ~52.4% in Q3, and the cash balance of ~$57M. Investors will also look for any update on a US filing for INTERCEPT red blood cells after the positive RedeS readout, the European CE Mark review, and the FDA review of the INT200 illuminator.
Who are Cerus's main competitors?
+
Direct competition in pathogen reduction comes from Terumo Blood and Cell Technologies, whose Mirasol system uses riboflavin and UV light, and from Macopharma's THERAFLEX UV technology, both mainly outside the US. INTERCEPT has the broadest regulatory footprint, including FDA approval for platelets and plasma. In practice, Cerus also competes with alternative ways of making platelets safe, such as large-volume delayed bacterial culture, rapid bacterial tests from companies like Verax Biomedical, and cold-stored platelets. For IFC, the competition is cryoprecipitate made by blood centers and fibrinogen concentrates from large plasma companies such as CSL Behring and Octapharma, which have more scale and broader hospital relationships than Cerus.
How did Cerus do in its latest quarter?
+
In the third quarter of 2026, reported November 2, Cerus grew product revenue about 10% to ~$57.7M and total revenue about 6% to ~$64.0M, including ~$6.3M of government contract revenue. The net loss was ~$0.6M, or about $0.00 per share, a cent better than the consensus estimate of a $0.01 loss, and adjusted EBITDA was ~$5.7M. Product gross margin was ~52.4%, down from ~53.4% a year earlier but up from the second quarter. Management reiterated 2026 product revenue guidance of ~$229M to $231M. The bigger news that day was the positive RedeS red blood cell readout.
How has CERS stock performed in 2026?
+
As of November 20, 2026, Cerus closed at ~$1.90, down about 3% year to date and up about 28% over the past year. The recent trend has been weaker: the stock fell about 18% over the last month and about 30% over three months, including the period after the positive RedeS readout and third-quarter results. Its 52-week range runs from ~$1.47 to ~$3.47, a wide band for a ~$385M company, which shows how sensitive the shares are to regulatory news. Past performance says nothing certain about future returns.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Cerus Corporation's investor relations page or your broker before making investment decisions.